| Primary |
| Prophylaxis |
27.2% |
| Non-small Cell Lung Cancer |
25.3% |
| Pain |
5.7% |
| Hypertension |
5.3% |
| Supplementation Therapy |
4.5% |
| Pleural Mesothelioma Malignant |
4.4% |
| Premedication |
3.7% |
| Nausea |
3.1% |
| Constipation |
2.8% |
| Cancer Pain |
2.6% |
| Non-small Cell Lung Cancer Stage Iv |
2.1% |
| Head And Neck Cancer |
2.0% |
| Insomnia |
1.8% |
| Non-small Cell Lung Cancer Stage Iii |
1.6% |
| Diabetes Mellitus |
1.5% |
| Chronic Obstructive Pulmonary Disease |
1.5% |
| Non-small Cell Lung Cancer Metastatic |
1.3% |
| Lung Neoplasm Malignant |
1.3% |
| Depression |
1.2% |
| Cough |
1.1% |
|
| Pneumonia |
10.2% |
| Vomiting |
9.7% |
| Pulmonary Embolism |
8.9% |
| White Blood Cell Count Decreased |
8.3% |
| Thrombocytopenia |
8.2% |
| Dyspnoea |
7.4% |
| Death |
6.0% |
| General Physical Health Deterioration |
5.2% |
| Sepsis |
4.6% |
| Pyrexia |
3.9% |
| Respiratory Failure |
3.8% |
| Dehydration |
3.4% |
| Pancytopenia |
3.1% |
| Renal Failure Acute |
3.1% |
| Platelet Count Decreased |
2.6% |
| Pleural Effusion |
2.6% |
| Neutropenia |
2.5% |
| Deep Vein Thrombosis |
2.3% |
| Renal Impairment |
2.3% |
| Syncope |
2.2% |
|
| Secondary |
| Non-small Cell Lung Cancer |
34.7% |
| Prophylaxis |
16.3% |
| Drug Use For Unknown Indication |
6.9% |
| Pain |
5.4% |
| Hypertension |
4.5% |
| Lung Neoplasm Malignant |
3.3% |
| Cancer Pain |
3.1% |
| Non-small Cell Lung Cancer Stage Iv |
2.8% |
| Pleural Mesothelioma Malignant |
2.5% |
| Supplementation Therapy |
2.3% |
| Constipation |
2.3% |
| Nausea |
2.3% |
| Insomnia |
1.9% |
| Lung Adenocarcinoma |
1.8% |
| Breast Cancer |
1.8% |
| Premedication |
1.7% |
| Non-small Cell Lung Cancer Stage Iii |
1.6% |
| Hodgkin's Disease |
1.6% |
| Non-hodgkin's Lymphoma |
1.6% |
| Product Used For Unknown Indication |
1.6% |
|
| Vomiting |
10.5% |
| Pneumonia |
9.7% |
| White Blood Cell Count Decreased |
8.3% |
| Thrombocytopenia |
6.7% |
| General Physical Health Deterioration |
5.7% |
| Weight Decreased |
5.5% |
| Pulmonary Embolism |
5.0% |
| Respiratory Failure |
4.8% |
| Dyspnoea |
4.7% |
| Pyrexia |
4.7% |
| Renal Failure |
4.7% |
| Anaemia |
4.5% |
| Renal Impairment |
4.3% |
| Death |
4.1% |
| Sepsis |
4.0% |
| Pancytopenia |
3.1% |
| Pericardial Effusion |
2.6% |
| Syncope |
2.6% |
| Rash |
2.4% |
| Dehydration |
2.2% |
|
| Concomitant |
| Non-small Cell Lung Cancer |
33.1% |
| Lung Neoplasm Malignant |
10.7% |
| Product Used For Unknown Indication |
9.4% |
| Drug Use For Unknown Indication |
6.2% |
| Lung Adenocarcinoma Metastatic |
4.7% |
| Nausea |
4.3% |
| Pain |
4.0% |
| Lung Adenocarcinoma |
3.7% |
| Lung Cancer Metastatic |
2.8% |
| Adenosquamous Cell Lung Cancer |
2.2% |
| Hypertension |
2.2% |
| Vomiting |
2.2% |
| Anxiety |
2.0% |
| Chemotherapy |
2.0% |
| Constipation |
2.0% |
| Premedication |
2.0% |
| Cough |
1.7% |
| Osteopenia |
1.7% |
| Prophylaxis |
1.7% |
| Bronchial Carcinoma |
1.5% |
|
| Rash |
10.7% |
| Weight Decreased |
9.5% |
| Vomiting |
8.3% |
| Weight Increased |
7.1% |
| Osteonecrosis Of Jaw |
6.0% |
| Pulmonary Embolism |
6.0% |
| Intestinal Perforation |
4.8% |
| Muscular Weakness |
4.8% |
| Pyrexia |
4.8% |
| Thrombocytopenia |
4.8% |
| Arterial Occlusive Disease |
3.6% |
| Haematotoxicity |
3.6% |
| Ileus |
3.6% |
| Loss Of Consciousness |
3.6% |
| Malignant Neoplasm Progression |
3.6% |
| Platelet Count Decreased |
3.6% |
| Renal Failure Acute |
3.6% |
| Sepsis |
3.6% |
| Aneurysm |
2.4% |
| Death |
2.4% |
|
| Interacting |
| Lung Neoplasm Malignant |
46.2% |
| Mesothelioma |
30.8% |
| Lung Carcinoma Cell Type Unspecified Stage Iv |
23.1% |
|
| Rectal Haemorrhage |
40.0% |
| Drug Interaction |
20.0% |
| Haematotoxicity |
20.0% |
| Platelet Count Decreased |
20.0% |
|
